(199 1) The use of selegiline in Alzheimer's patients with behavior
problems. J Clin Psycho1 52:342-345.
Grimsby J, Chen K, Wang L-J, Lan NC, Shih JC (1991) Human
monoamine oxidase A and B genes exhibit identical exon-intron
organization. Proc Nat1 Acad Sci USA 88:3637-3641.
Grothe C, Unsicker K (1992) Basic fibroblast growth factor in the
hypoglossal system: specific retrograde transport, trophic and lesionrelated responses. J Neurosci Res 32:3 17-328.
Halman H, Jonsson GH (1984) Pharmacological modification of the
neurotoxic action of the noradrenaline neurotoxin DSP-4 on central
noradrenaline neurons. Eur J Pharmacol 103:269-278.
Heinonen EH, Lammintausta R (199 1) A review of the pharmacology
of selegiline. Acta Neurol Stand 84:44-59.
Heinonen EH, Myllylla V, Sotaniemi K, Lamintausta R, Salonen JS,
Anttila M, Savijlrvi M, Kotila M, Rinne UK (1989) Pharmacokinetics and metabolism of selegiline. Acta Neurol Stand [Suppl] 126:
93-99.
Hirano M, Goldman JE (1988) Gliogenesis in the rat spinal cord:
evidence for origin of astrocytes and oligodendrocytes from radial
precursors. J Neurosci Res 21: 155-167.
Hoover DB, Hancock JC (1985) Effect of facial nerve transection on
acetylcholinesterase, choline acetyltransferase, and tritium quinuclidinyl benzilate binding in rat facial nuclei. Neuroscience 15:48 l-488.
Horsing LG, Magyar K, Tekes K, Vizi ES, Knoll J (1979) Inhibition
of dopamine uptake by deprenyl in rat striatum: a possible correlate
between dopamine uptake and acetyl choline release inhibition. Pol
J Pharmacol Pharm 3 1:297-307.
Johnston JP (1968) Some observations upon a new inhibition of
monoamine oxidase in brain tissue. Biochem Pharmacol 17:43 l-435.
Kalari RN, Mitchell MJ, Harik SI (1988) Monoamineoxidases of the
human brain and liver. Brain 111: 144 1-145 1.
Karoum F, Chuang LW, Eisler T, Calne DB, Liebowitz MR, Quitkin
FM, Klein DF, Wyatt RJ (1982) Metabolism of (-)deprenyl to
amphetamine and methamphetamine may be responsible for de- prenyl's therapeutic benefit: a biochemical assessment. Neurology 32:
503-509.
Lieberman A, Fahn S, Olanow CW, Tetrud JW, Koller WC, Calne D,
Fazzini EA, Muenter MD (1992) Does selegiline provide a symptomatic or a neuroprotective effect-discussion. Neurology 42:4 1118.
Linder JC, Klemfuss H, Groves PM (1987) Acute ultrastructural and
behavioral effects of 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine
(MPTP) in mice. Neurosci Lett 82:22 l-226.
Mangoni A, Grassi MP, Frattola L, Piolti R, Bassi S, Motta A, Marcone
A. Smirne S (199 1) Effects of an MAO-B inhibitor in the treatment
of Alzheimer's disease. Eur Neurol 3 1: 100-107.
Martignoni E, Bono G, Blandini F, Sinforiani E, Merlo P, Nappi G
(1991) Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type: influence of
treatment with L-deprenyl. J Neural Transm [Parkinson's Dis De- mentia] 3: 15-26.
Monteverde A, Gnemmi P, Rossi F, Monteverde A, Finali GC (1990)
Selegiline in the treatment of mild to moderate Alzheimer-type de- mentia. Clin Ther 12:3 15-322.
Myllyla VV, Sotaniemi KA, Vuorinen JA, Heinonen EH (1992) Se- legiline as initial treatment in de nova parkinsonian patients. Neurology 42:339-343.
Olannw CW, Calne D (1992) Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms? Neurology 42: 13-26.
Oppenheim RW (1986) The absence of significant postnatal motoneuron death in the brachial and lumbar cord of the rat. J Comp
Neurol 246:28 l-286.
Parkinson Study Group (1989) Effect of deprenyl on the progression
of disabilitv in earlv Parkinson's disease. N Engl J Med 321: 1364-1371. _ .
Parkinson Study Group (1993) Effects of tocopherol and deprenyl on
the nroaression of disabilitv in earlv Parkinson's disease. N Engl J
Med 328:176-183. .Paterson IA, Juorio AV, Boulton AA (1990a) 2-Phenylethylamine: a
modulator of catecholamine transmission in the mammalian central
nervous system? J Neurochem 55:1827-1837.
Paterson IA, Juorio AV, Boulton AA (1990b) Possible mechanism of
action of deprenyl in parkinsonism. Lancet 336: 183.
Piccinin GL, Finali G, Piccirilli M (1990) Neuropsychological effects
of L-deprenyl in Alzheimer's type dementia. Clin Neuropharmacol
13:147-163.
